U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172282) titled 'INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases' on Sept. 03.
Brief Summary: Nelitolimod is a classC toll-like receptor 9 (TLR9) agonist that binds to TLR9 receptors on myeloid-derived suppressor cells(MDSCs) and helps reshape the tumor microenvironment (TME) and promote antitumor immunity. Investigators hypothesize that Nelitolimod can induce antitumor immune response in CRLM when administered regionally to the liver via a TriNav Pressure Enabled Drug Delivery (PEDD) catheter without compromising surgical feasibility or patient safety.
The study objective is to investigate the feasibility and safety of an ...